Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients

Transplantation Proceedings

Volumn 42, Issue 9, 2010, Pages 3455-3458

  Rong, G ^a   Jing, L ^a   Deng Qing, L ^a   Hong Shan, Z ^b   Shai Hong, Z ^a   Xin Min, N ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENOTYPE; GRAFT RECIPIENT; HETEROZYGOTE; HUMAN; KIDNEY CLEARANCE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STEADY STATE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; CHINA; CYTOCHROME P-450 CYP3A; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; P-GLYCOPROTEIN; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; STEROIDS; TACROLIMUS; YOUNG ADULT;

EID: 78649474351     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.08.063     Document Type: Article

References (16)

1. D.A. Hesselink, R.H. van Schaik, and I.P. van der Heiden Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 74 2003 245
2. Y. Zhang, and L.Z. Benet The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein Clin Pharmacokinet 40 2001 159
3. H. Tada, N. Tsuchiya, and S. Satoh Impact of CYP3A5 and MDR1 (ABCB1) 3435T>C polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplant Proc 37 2005 1730
4. P. Kelly, and B.D. Kahan Metabolism of immunosuppressant drugs Curr Drug Metab 3 2002 275
5. P. Kuehl, J. Zhang, and Y. Lin Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 2001 383
6. P.B. Watkins The barrier function of CYP3A4 and P-glycoprotein in the small bowel Adv Drug Deliv Rev 27 1997 161
7. A. Ayrton, and P. Morgan Role of transport proteins in drug absorption, distribution and excretion Xenobiotica 31 2001 469
8. S. Hoffmeyer, O. Burk, and O. von Richter Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 97 2000 3473
9. R. Venkataramanan, A. Swaminathan, and T. Prasad Clinical pharmacokinetics of tacrolimus Clin Pharmacokinet 29 1995 404
10. J.K. Lamba, Y.S. Lin, and E.G. Schuetz Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Deliv Rev 54 2002 127
11. P.A. Andrews, M. Sen, and R.W. Chang Racial variation in dosage requirements of tacrolimus Lancet 348 1996 1446
12. X.M. Nie, Z.F. Huang, and R. Gui Influence of CYP3A5 polymorphism on the tacrolimus blood concentrations in renal transplant patients Chin J Org Trans 11 2005 698
13. Y. Zhao, M. Song, and D. Guan Genetic polymorphisms of CYP3A5 genes and concentrations of the cyclosporine and tacrolimus Transplant Proc 37 2005 178
14. M.F. Fromm The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans Adv Drug Deliv Rev 54 2002 1295
15. N. von Ahsen, M. Richter, and C. Grupp No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients Clin Chem 47 2001 1048
16. S.V. Ambudkar, C. Kimchi-Sarfaty, and Z.E. Sauna P-glycoprotein: from genomics to mechanism Oncogene 22 2003 7468